Exagen Inc (XGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Exagen Inc (XGN) has a cash flow conversion efficiency ratio of 0.326x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.99 Million) by net assets ($12.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Exagen Inc (XGN) market capitalisation for the company's overall valuation and market capitalisation.
Exagen Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Exagen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Exagen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Exagen Inc ranked by their cash flow conversion efficiency. See XGN cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Northcliff Resources Ltd
TO:NCF
|
-0.049x |
|
Dong Nai Port JSC
VN:PDN
|
0.070x |
|
SC II Acquisition Corp. Class A ordinary share
NASDAQ:SCII
|
-0.001x |
|
Compania Espanola de Viviendas en Alquiler SA
MC:CEV
|
0.006x |
|
Elanders AB (publ)
ST:ELAN-B
|
0.112x |
|
Value Added Technology Co. Ltd
KQ:043150
|
0.022x |
|
Expensify Inc
NASDAQ:EXFY
|
0.063x |
|
Spandana Sphoorty Financial Limited
NSE:SPANDANA
|
0.597x |
Annual Cash Flow Conversion Efficiency for Exagen Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Exagen Inc from 2012 to 2025. View XGN stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.45 Million | $-13.62 Million | -0.781x | +43.90% |
| 2024-12-31 | $9.54 Million | $-13.28 Million | -1.392x | -118.42% |
| 2023-12-31 | $22.69 Million | $-14.46 Million | -0.637x | +15.82% |
| 2022-12-31 | $42.46 Million | $-32.14 Million | -0.757x | -217.23% |
| 2021-12-31 | $84.94 Million | $-20.27 Million | -0.239x | +29.11% |
| 2020-12-31 | $41.84 Million | $-14.08 Million | -0.337x | -92.94% |
| 2019-12-31 | $55.66 Million | $-9.71 Million | -0.174x | -112.63% |
| 2018-12-31 | $-6.73 Million | $-9.30 Million | 1.381x | -41.59% |
| 2017-12-31 | $-4.64 Million | $-10.97 Million | 2.365x | +340.77% |
| 2015-12-31 | $-22.18 Million | $-11.90 Million | 0.537x | -30.00% |
| 2014-12-31 | $-14.06 Million | $-10.77 Million | 0.766x | +105.04% |
| 2013-12-31 | $451.00K | $-6.87 Million | -15.222x | -881.67% |
| 2012-12-31 | $4.82 Million | $-7.48 Million | -1.551x | -- |
About Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead test… Read more